Lestaurtinib Completed Phase 2 Trials for Myeloid Leukemias Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00030186Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation